Daily Roundup

AVH.ASX AHC.ASX DSE.ASX NHC.ASX FND.ASX

New Hope Corporation Reports Strong H1 FY25 Results

New Hope Corporation Limited has reported a net profit after tax of $340.3 million for the half-year ended 31 January 2025, representing a 35.2% increase from the previous corresponding period. The company's underlying EBITDA result was $517.3 million, an increase of 21.8% compared to the prior period.

The improved financial performance was driven by increased coal production, lower unit costs, and solid realised pricing, which remained above long-term historical averages. Bengalla Mine and New Acland Mine recorded strong operational performances, with Group Run-of-Mine (ROM) coal production of 8.3Mt and saleable coal production of 5.4Mt, increases of 56.2% and 32.9% respectively compared to the previous period. Coal sales increased by 43.5% to 5.4Mt for the period.

Group Free on Rail (FOR) cash costs decreased by 23.5% to $55.5/tonne, and Group Free on Board (FOB) cash costs (excluding royalties and trade coal) were 20.6% lower at $77.7/t. The company generated operating cash flows of $316.9 million, a 142.6% increase from the prior period.

New Hope continues to focus on disciplined capital management and providing valuable returns to shareholders, declaring a 2025 interim dividend of 19.0 cents per share, fully franked.

Austco Secures Largest SMA Contract in Company History

Austco Healthcare Limited's (ASX: AHC) subsidiary Austco Marketing & Service (Canada) has secured a contract valued at AUD $1.02 million for a 5-year Software and Maintenance Agreement (SMA) with West Park Hospital, one of the company's largest customers. The agreement will commence on 1 April 2025 and represents the largest SMA contract in Austco's history, further reinforcing the company's strategic focus on expanding recurring software and service revenues.

By securing long-term SMA agreements, Austco strengthens its revenue predictability while ensuring customers receive ongoing support, software upgrades, and system enhancements that provide long-term value. The contract renewal emphasizes the significance of Austco's strategic initiative to boost recurring software revenues and highlights the increasing demand for the company's healthcare communications solutions, as well as the trust customers have in Austco's ability to deliver mission-critical products and support.

Dropsuite Provides Update on Topline Capital Partners LP

Dropsuite Limited (ASX: DSE) has received a written communication from Topline Capital Partners LP, advising of its current shareholding of approximately 7.36 million shares (10.47% of issued capital) and its continued support for the proposed transaction with NinjaOne.

This is a decrease from the previous holding of 13,829,409 shares (19.7% of issued capital) disclosed in Topline Capital's Form 604 dated 18 February 2025. Despite the reduced shareholding, Topline Capital has advised the Company that it remains highly supportive of the proposed transaction.

Findi Ltd Requests Trading Halt

Findi Ltd (ASX: FND) has requested a trading halt on its ordinary shares quoted on the Australian Securities Exchange (ASX). The trading halt has been requested pending an announcement by the company to the market in relation to a capital raising.

The trading halt will remain in place until the earlier of the commencement of normal trading on Thursday, 20 March 2025, or when the announcement regarding the capital raising is released to the market.

AVITA Medical Announces New Manufacturing and Distribution Agreements

AVITA Medical, Inc. has announced it has entered into a new Contract Manufacturing Agreement for PermeaDerm Biosynthetic Wound Matrix, along with an Amendment to its existing Exclusive Distribution Agreement with Stedical Scientific, Inc. These agreements further strengthen the strategic relationship between the two companies to expand the reach and availability of PermeaDerm.

Under the new Contract Manufacturing Agreement, effective March 17, 2025, AVITA Medical will manufacture PermeaDerm at its state-of-the-art facility in Ventura, California. The Exclusive Distribution Agreement has also been amended to align with the new manufacturing arrangement, modifying revenue-sharing terms and establishing performance-based milestones.